Ophthalmic Devices Market Size & Share 2026-2035

Ophthalmic Devices Market Size

The global ophthalmic devices market was valued at USD 50.7 billion in 2025, and is projected to USD 85.1 billion by 2035, representing a 5.4% CAGR over 2026–2035.

Vision care products account for the largest revenue base, while diagnostic and monitoring devices are expected to outpace the overall market as imaging, measurement, and disease-monitoring workflows become more data intensive.

Demand is anchored in the scale and heterogeneity of visual impairment. The World Health Organization estimates that at least 2.2 billion people live with near or distance vision impairment, including 94 million affected by cataract, 88.4 million by refractive error, 8 million by age-related macular degeneration, 7.7 million by glaucoma, and 3.9 million by diabetic retinopathy ^{[1]World Health Organization, *Blindness and Visual Impairment*, who.int}. Glaucoma creates a particularly long-duration monitoring requirement: the global population aged 40–80 with glaucoma was projected to rise from 76.0 million in 2020 to 111.8 million in 2040, with Asia and Africa accounting for a disproportionate share of the increase ^{[2]PubMed, *Global Prevalence of Glaucoma and Projections of Glaucoma Burden Through 2040*, pubmed.ncbi.nlm.nih.gov}.

The market spans high-volume refractive correction, capital-intensive diagnostics, and procedural technologies whose purchasing cycles differ substantially. Contact lenses and spectacle lenses are shaped by consumer replacement behavior and myopia-management adoption, whereas surgical and diagnostic platforms depend more heavily on reimbursement, clinical throughput, service infrastructure, and provider capital budgets.

The fastest strategic opportunity sits where disease burden creates repeated interaction with the care pathway. Glaucoma and diabetic retinopathy require longitudinal surveillance, while myopia and presbyopia create recurring correction needs. Suppliers that combine durable clinical platforms with consumables, software-enabled monitoring, or replacement products are therefore better positioned than suppliers dependent on isolated capital-equipment transactions.

Key Drivers

Increase in the number of people suffering from ophthalmic disorders

Cataract, uncorrected refractive error, glaucoma, retinal disease, and diabetic retinopathy create demand across different device categories rather than within a single treatment setting. Cataract remains the leading cause of blindness among adults aged 50 years and older, affecting more than 15 million people with blindness globally in 2020 ^{[3]International Agency for the Prevention of Blindness, *Causes of Blindness and Vision Impairment in 2020*, iapb.org}. Its treatment requires a coordinated ecosystem of diagnostic measurement, phacoemulsification equipment, IOLs, surgical consumables, and postoperative monitoring. Retinal and glaucoma disease, by contrast, increase the value of imaging, visual-field assessment, tonometry, and repeat clinical follow-up.

Disease prevalence also changes the mix of demand. A higher share of chronic retinal and glaucoma cases supports recurring diagnostic utilization, while rising refractive error expands the addressable market for spectacle lenses, contact lenses, refractive surgery, and myopia-management products. The market therefore benefits from both episodic procedure demand and chronic monitoring demand.

Technological advancements in products

Technology is moving ophthalmology from isolated examinations toward data-supported diagnosis and more controlled procedures. In a randomized comparison, femtosecond laser-assisted cataract surgery produced lower endothelial cell loss than conventional phacoemulsification at both three months and one year ^{[4]Frontiers in Medicine, *Comparison of Femtosecond Laser-Assisted Cataract Surgery and Conventional Phacoemulsification: A Randomized Controlled Trial*, frontiersin.org}. Such clinical differentiation can support adoption in premium surgical settings, although the commercial case remains dependent on capital cost, surgeon workflow, and patient willingness to pay.

MIGS has strengthened the role of combined cataract and glaucoma procedures. A 2025 systematic review found that adding MIGS to cataract surgery reduced intraocular pressure by a pooled mean of 1.58 mmHg versus cataract surgery alone and reduced medication use by 0.79 medications ^{[5]PubMed Central, *Outcomes of Minimally Invasive Glaucoma Surgery Combined With Cataract Surgery: A Systematic Review and Meta-analysis*, pmc.ncbi.nlm.nih.gov}. The implication is not that every cataract procedure becomes a glaucoma-device opportunity; rather, the value of MIGS concentrates where diagnosed glaucoma, medication burden, and surgical candidacy overlap.

Favorable government initiatives

Public eye-health programs enlarge the market principally by converting unmet need into screening, referral, and treatment volumes. WHO's World Report on Vision positioned integrated eye care within universal health coverage and built on a series of World Health Assembly actions on avoidable visual impairment . The policy effect is most meaningful when screening capacity, trained personnel, referral pathways, and procedure financing develop together.

India illustrates the scale that a national program can create. The National Programme for Control of Blindness and Visual Impairment has operated since 1976, while the 2015–2019 national survey found that cataract accounted for 66.2% of blindness among Indians aged 50 years and older ^{[6]India Vision Atlas / National Programme for Control of Blindness and Visual Impairment, *National Blindness and Visual Impairment Survey 2015-2019*, indiavisionatlasnpcb.aiims.edu}. More than 9.8 million cataract surgeries were reported under the program in FY2024–25 ^{[7]India Tribune, *Over 98 Lakh Cataract Surgeries Performed in FY25, Highest in Last Five Years*, indiatribune.com}. Large procedural volumes support demand for surgical equipment and consumables, but they also heighten the importance of service networks, dependable supply, and standardized clinical workflows.

Rising adoption of contact lenses and spectacles

The replacement market is becoming more technologically differentiated. Across 20 countries, daily disposable lenses increased from 17.1% of daily-wear soft-lens fits in 2000 to 46.7% in 2023 ^{[8]Contact Lens & Anterior Eye, *Daily Disposable Contact Lens Prescribing Trends in 20 Countries Between 2000 and 2023*, sciencedirect.com}. Daily disposables increase the frequency of purchase and reduce dependence on lens-care routines, but they also require manufacturers and eye-care providers to maintain broad prescription availability across spherical, toric, and multifocal designs.

Myopia provides a longer-term demand driver. A meta-analysis covering 276 studies projected that myopia prevalence among children and adolescents would increase from 35.81% in 2023 to 39.80% by 2050 . This enlarges the market for conventional correction while also creating a differentiated category for products designed to manage progression. Product launches that address combinations of astigmatism, presbyopia, and myopia management indicate that innovation is shifting toward more complex prescriptions rather than undifferentiated lens volume.

Key Restraints

High cost of ophthalmic devices

Capital intensity and patient out-of-pocket exposure restrict adoption of premium ophthalmic technologies. Premium IOL surgery can cost an estimated USD 3,000–5,000 per eye in settings where presbyopia-correcting lenses are not reimbursed ^{[9]European Society of Cataract and Refractive Surgeons, *Overcoming Barriers to Presbyopic IOL Uptake*, escrs.org}. The affordability constraint affects more than elective upgrades: it can determine whether providers invest in premium diagnostic or surgical equipment and whether patients accept technologies with potential clinical or lifestyle advantages.

Coverage design materially affects adoption. In Taiwan, premium IOL use increased from 35.2% in 2016 to 42.6% in 2020 under the national health insurance system, but uptake remained higher among younger and higher-income patients and at medical centers . This demonstrates that device innovation can widen clinical choice without producing uniform access. Suppliers targeting premium segments must therefore align product design with financing, provider training, and the economics of patient conversion.

Increasing adoption of refurbished ophthalmic devices

Refurbished equipment creates an alternative route to diagnostic and procedural capacity for cost-constrained providers, particularly where new capital equipment is unaffordable. Refurbishment demand is supported by budget pressure, sustainability objectives, and expansion of care infrastructure in emerging markets, although regulatory approaches to refurbished medical equipment remain fragmented . Import restrictions and inconsistent standards across APEC economies can constrain cross-border availability even when clinical demand exists ^{[10]Asia-Pacific Economic Cooperation, *Trade in Remanufactured Goods in APEC: The Case of Refurbished Medical Imaging Devices*, apec.org}.

For new-equipment suppliers, the restraint is most acute in standardized imaging and procedure categories where an installed platform can retain utility after refurbishment. The effect is less uniform in products with high consumables intensity, rapidly changing software, or substantial service requirements. This makes lifecycle support, upgrade pathways, and trade-in programs commercially important tools for protecting installed-base relationships.

Refurbishment intensifies this segmentation rather than eliminating demand for new technology. It is most likely to compete where providers prioritize initial acquisition cost and can operate established platforms without the latest features. New-device suppliers retain stronger positions where clinical performance, integrated software, consumable pull-through, regulatory support, and service continuity matter more than acquisition price alone.

Ophthalmic Devices Segment Analysis

By Product

Vision care products generated USD 26,219.22 million in 2025, representing 51.74% of the market, and are projected to grow at a 5.31% CAGR. Contact lenses-including soft, RGP, toric, and other lenses-benefit from replacement demand and increasing prescription complexity. Spectacle lenses remain the broadest correction category, supported by high refractive-error prevalence and aging-related presbyopia. The shift toward daily disposable, toric, multifocal, and myopia-management lenses increases the value of fit expertise and product breadth relative to standard spherical correction.

Surgical devices accounted for USD 11,612.52 million in 2025 and are projected to grow at a 5.08% CAGR. Cataract surgery devices, including IOLs, phaco devices, OVDs, cataract surgical lasers, IOL injectors, and other devices, remain the core surgical category because cataract surgery is among the most common procedures globally, with approximately 3.8 million procedures annually in the U.S., 4.3 million in Europe, and more than 20 million internationally . Glaucoma surgery devices-including drainage devices, glaucoma lasers, MIGS, and other devices-benefit from the expanding role of combined interventions. Refractive surgery devices-excimer lasers, femtosecond lasers, and other devices-and vitreoretinal surgery devices-photocoagulation lasers, illumination devices, vitreoretinal packs, vitrectomy machines, vitrectomy probes, and other devices-address more specialized procedural needs and depend on surgeon concentration and capital availability.

Diagnostic and monitoring devices generated USD 9,438.30 million in 2025, or 18.62% of revenue, and are forecast to grow at the fastest product-category rate of 6.00%. Autorefractors, biometers, corneal topographers, fundus cameras, keratometers, lensmeters, ophthalmic ultrasound systems, ophthalmoscopes, optical biometers, OCT scanners, pachymeters, perimeters/visual field analyzers, phoropters, retinoscopes, slit lamps, specular microscopes, tonometers, wavefront aberrometers, and other devices increasingly sit at the intersection of screening, diagnostic precision, procedural planning, and chronic-disease monitoring. The segment's higher growth reflects the need to monitor glaucoma, diabetic retinopathy, and retinal disease over time rather than only at the point of treatment.

Ophthalmic accessories accounted for USD 3,408.64 million in 2025 and are expected to expand at a 5.70% CAGR. Although smaller than the other product categories, accessories support the usability, safety, and continuity of examination and surgical workflows. Their revenue profile is linked to installed equipment, clinical volumes, replacement cycles, and procedural activity.

By End Use

Consumers accounted for 47.7% of market demand in 2025, reflecting the scale of contact lenses, spectacle lenses, and other direct-use vision-care products. Consumer demand is sensitive to prescription trends, disposable income, distribution access, and the availability of designs that address astigmatism, presbyopia, and myopia progression.

Hospitals remain important purchasers of surgical platforms and advanced diagnostic systems because they manage higher-acuity cases and integrate ophthalmology with broader care pathways. Specialty clinics are projected to grow at a 6.2% CAGR, supported by focused diagnostic capacity, elective refractive care, and recurring chronic-disease monitoring. Their commercial advantage lies in concentrated expertise and patient throughput, although capital utilization must remain high enough to support advanced equipment.

Ambulatory surgery centers are projected to grow at a 5.5% CAGR. In the U.S., the share of cataract surgeries performed in ASCs increased from 43.6% in 2001 to 73.0% in 2014, while average patient copayments in 2014 were lower at ASCs than in hospital outpatient settings . This setting favors compact, reliable surgical workflows and may accelerate adoption of devices that reduce turnover time, simplify procedures, or support predictable outcomes. Other end users include academic institutions, optical retailers, and public screening programs.

The more rapid expansion of diagnostic and monitoring devices reflects a different economic logic. Chronic ophthalmic disease requires repeat measurement, creating demand for imaging and functional-testing infrastructure even when definitive treatment is deferred. Surgical-device growth remains substantial but is more exposed to procedural capacity, reimbursement, and capital budgets. End-use migration toward specialty clinics and ASCs reinforces the value of devices that support high throughput, serviceability, and reliable outcomes outside large hospital settings.

Ophthalmic Devices Market Regional Analysis

North America

North America accounted for 36.62% of the global market in 2025, equivalent to USD 18,558.53 million, and is projected to grow at a 4.78% CAGR. The U.S. represented 92.27% of regional revenue, or approximately USD 17,121.26 million, while Canada accounted for 7.73% and is expected to grow faster at a 5.48% CAGR. Vision care products generated USD 9,573.07 million in North America in 2025, followed by surgical devices at USD 4,118.15 million, diagnostic and monitoring devices at USD 3,600.71 million, and accessories at USD 1,266.60 million.

High chronic-disease detection needs support diagnostic demand in the U.S. An estimated 9.6 million people had diabetic retinopathy in 2021, including 1.84 million with vision-threatening disease ^{[11]Centers for Disease Control and Prevention, *Prevalence of Diabetic Retinopathy in the United States*, cdc.gov}. Yet utilization gaps remain material: only 54.1% of Medicare beneficiaries with diabetes received an eye examination in 2017, with lower rates among non-Hispanic Black and Hispanic beneficiaries . The combination of disease burden and incomplete screening creates a market for accessible diagnostic and monitoring pathways, although reimbursement and provider-network coverage determine whether demand converts into equipment placement.

Europe

Europe represented 28.13% of the global market in 2025, or USD 14,261.07 million, and is forecast to expand at a 5.19% CAGR. Germany, the UK, France, Spain, Italy, and the Netherlands are the principal covered markets. Aging-related retinal disease, cataract, glaucoma, and diabetic eye disease sustain demand for both diagnosis and treatment. EURETINA estimated that 34 million people in the EU were affected by retinal diseases, with diabetic eye disease affecting more than one-quarter of diabetic patients in the region ^{[12]European Society of Retina Specialists, *Retinal Diseases in Europe*, miloftalmica.it}.

Regulation is a meaningful commercial variable in Europe. Regulation (EU) 2017/745 applies to ophthalmic medical devices and raises requirements for conformity assessment, post-market surveillance, and documentation ^{[13]European Union, *Regulation (EU) 2017/745 on Medical Devices*, eur-lex.europa.eu}. For manufacturers, MDR compliance can increase time and cost to sustain product portfolios, particularly where device classifications require notified-body involvement. The burden may reinforce the position of suppliers with established regulatory infrastructure while making smaller or legacy-product portfolios harder to maintain.

Asia Pacific

Asia Pacific accounted for 26.96% of global revenue in 2025, equivalent to USD 13,662.87 million, and is projected to record the highest regional CAGR at 6.35%. China, Japan, India, Australia, and South Korea combine large refractive-correction populations with expanding cataract and retinal-care requirements. In China, pooled myopia prevalence among children was 38.0%, with higher prevalence in urban populations . This supports sustained demand for spectacle lenses, contact lenses, and myopia-management products.

India adds a high-volume surgical dimension. Cataract's large contribution to blindness and the scale of the national cataract program make cost-efficient surgical systems, consumables, and service support important to market access. Australia and other mature Asia Pacific markets support advanced diagnostic and treatment adoption, while public-health programs continue to shape demand for screening and preventive care. The region's growth advantage rests on a mix of consumer refractive demand, expanding procedure volume, and greater diagnostic penetration rather than a uniform premium-device market.

Latin America

Latin America accounted for 5.18% of global revenue in 2025 and is projected to grow at a 5.87% CAGR. Brazil, Mexico, and Argentina form the covered markets. Regional demand is shaped by the gap between disease burden and access to cataract surgery, refractive correction, and specialist services. Evidence from Latin America identifies lower cataract surgical coverage in rural and low-income populations, with a persistent divide between private and public provision .

This access structure favors suppliers that can adapt commercial models to fragmented provider networks and public procurement constraints. Demand for lower-cost equipment, serviceable installed systems, and consumable-efficient procedural technologies can be stronger than demand for premium capital platforms. Private clinic networks may create concentrated purchasing opportunities, but adoption remains sensitive to financing and geographic inequities in care access.

Middle East and Africa

Middle East and Africa represented 3.10% of global revenue in 2025 and are projected to expand at a 5.50% CAGR. South Africa, Saudi Arabia, and the UAE are the covered markets. In Gulf Cooperation Council countries, a meta-analysis estimated diabetic retinopathy prevalence at 20.5%, reinforcing demand for retinal imaging, screening, and treatment capacity . Saudi Arabia's Health Sector Transformation Program seeks to expand private-sector participation in healthcare, including a target increase in the private share of hospital beds from 23% to 68% by 2030 ^{[14]Saudi Vision 2030, *Health Sector Transformation Program*, vision2030.gov.sa}.

Across much of sub-Saharan Africa, the need is more strongly shaped by preventable or treatable visual impairment and limited service capacity. WHO estimates that the African Region has 20.4 million people with low vision and 5.9 million who are blind, with up to 80% of blindness preventable or treatable . Market development consequently depends on the availability of basic diagnostic equipment, cataract surgical capacity, trained personnel, and sustainable maintenance models as much as on demand for advanced technologies.

Europe's regulatory environment creates both a barrier and a competitive filter. MDR compliance can favor companies able to manage documentation, surveillance, and certification costs, while the region's aging population sustains clinical demand. Latin America, the Middle East, and Africa require more segmented commercial strategies: concentrated private investment may coexist with large public-access gaps, making financing, serviceability, training, and procurement design as decisive as product performance.

Ophthalmic Devices Market Share & Competitive Landscape

Competition spans consumer vision care, surgical systems, IOLs, diagnostic imaging, refraction, and ophthalmic examination equipment. Alcon, Bausch + Lomb, Johnson & Johnson Vision, CooperVision, Essilor, HOYA, ZEISS, NIDEK, TOPCON Healthcare, Canon, COBURN TECHNOLOGIES, HAAG-STREIT GROUP, HEINE, ophtec, VISIONIX, and ziemer OPHTHALMOLOGY participate through differing product portfolios and geographic routes to market.

Alcon combines contact lenses, IOLs, cataract equipment, and vitreoretinal systems. In 2025, the company introduced the UNITY Vitreoretinal Cataract System and UNITY Cataract System, emphasizing operating-room workflow across cataract and vitreoretinal procedures . It also expanded its premium IOL portfolio with Clareon PanOptix Pro in the U.S. . Its proposed acquisition of STAAR Surgical signals a strategic interest in expanding exposure to implantable refractive correction.

Bausch + Lomb's portfolio spans surgical and vision-care products. The FDA approved the enVista Envy IOL in December 2024, adding a presbyopia-correcting IOL option to the company's surgical offering ^{[15]U.S. Food and Drug Administration, *Premarket Approval P240005S002: enVista Envy Intraocular Lens*, accessdata.fda.gov}. Johnson & Johnson Vision launched ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM in the U.S. and Canada in June 2025, addressing the combined presbyopia-and-astigmatism segment . These developments illustrate how major suppliers are using prescription complexity to defend pricing and differentiate mature contact-lens and IOL categories.

CooperCompanies, through CooperVision, has established a position in myopia management. MiSight 1 day is FDA approved for slowing myopia progression in children aged 8–12 and is available in more than 40 countries ^{[16]CooperVision, *CooperVision Reinforces Myopia-Management Leadership*, coopervision.com}. CooperVision also launched MiSight Spectacle Lenses in Canada in 2025, broadening its approach beyond contact lenses . Essilor's competitive role is concentrated in ophthalmic lens technology and upstream materials, while HOYA remains focused on spectacle-lens innovation, including lenses designed for emerging presbyopes ^{[17]PR Newswire / HOYA Vision Care, *HOYA Vision Care Announces VisuPro Advanced Focus Lenses*, prnewswire.com}.

ZEISS, NIDEK, TOPCON Healthcare, Canon, HAAG-STREIT GROUP, HEINE, VISIONIX, COBURN TECHNOLOGIES, ophtec, and ziemer OPHTHALMOLOGY compete across imaging, diagnostics, refraction, visualization, examination, lens-processing, and surgical categories. ZEISS expanded U.S. distribution of the MICOR 700 handheld lens-removal device in 2024 ^{[18]ZEISS Medical Technology, *MICOR 700 Broad U.S. Distribution*, zeiss.com}. NIDEK and TOPCON Healthcare participate in diagnostic and imaging workflows, where integration of multiple measurements and imaging modalities is becoming increasingly important. For companies without documented eligible recent launch evidence, competitive positioning is assessed through their established product-category participation rather than unsupported claims regarding approvals, launches, or clinical performance.

Recent Industry Developments

• In July 2025, EssilorLuxottica agreed to acquire PUcore's division dedicated to the development, manufacture, and sale of monomers for high-index ophthalmic lenses. The transaction includes research and development capabilities, a production facility, a South Korean sales office, and related intellectual property, extending EssilorLuxottica's involvement in the upstream ophthalmic-lens materials chain .

• In August 2025, Alcon agreed to acquire STAAR Surgical for a total equity value of approximately USD 1.5 billion through an all-cash offer of USD 28 per share. The proposed acquisition adds the EVO Implantable Collamer Lens family to Alcon's portfolio and expands its presence in surgical refractive correction .

• In September 2025, Bausch + Lomb launched the ASANA gas-permeable lens portfolio in the U.S., expanding its specialty contact-lens offering .

• In September 2025, Johnson & Johnson launched its daily disposable toric contact lens designed for astigmatic patients in the UK and Ireland, extending a product category introduced earlier in North America.